SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE)-- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop ...
The American Association for Cancer Research (AACR) meeting kicks off this weekend, in San Diego, California. The event is a whirlwind of sessions, keynotes, mini-symposia, posters and exhibitors. How ...
SAN MATEO, Calif. and CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and ...
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE)-- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of ...
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that it will participate in the 36th edition of the ...
Abstract highlights:ORIC-114 is a highly selective, brain penetrant, orally bioavailable, irreversible inhibitor that selectively targets EGFR and HER2 with high potency against exon 20 insertion ...
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences, a clinical stage biopharmaceutical company, announced that ASN007 clinical data on safety, efficacy and pharmacokinetics in solid tumor ...
BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering unique pseudo-irreversible target inhibition Mutant selective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results